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Acoustic startle reflex (ASR) 
The ASR is a protective reflex that consists of a fast twitch of 
facial and body muscles, elicited by sudden and intense 
acoustic stimuli. 
 
Attentional set shift task 
(ASST) 
The ASST was established in rodents as an equivalent of the 
human WCST and involves a series of compound perceptual 
discriminations (e.g. odor and digging medium) that require 
subjects either to maintain attention and discriminate between 
two stimuli within one modality, or shift attention between two 
stimuli from two different modalities. 
 
Depolarisation-induced 
suppression of inhibition (DSI) 
or excitation (DSE) 
DSI and DSE are two related forms of short-term synaptic 
plasticity of GABAergic and glutamatergic transmission, 
respectively. They are induced by postsynaptic depolarisation 
and calcium-dependent synthesis of a retrograde acting 
endocannabinoids, which reversibly inhibit  neurotransmitter 
release via CB1 cannabinoid receptor mediated presynaptic 
mechanisms. DSI and DSE are thought to reflect two main 
mechanisms of endocannabinoid signaling. 
 
Elevated plus maze (EPM) 
The EPM is a classical paradigm for measuring anxiety-related 
behaviors in rodents. It consists of a plus-shaped, elevated 
apparatus with two opposed open, highly illuminated arms and 
two opposed closed arms. Exploration of the aversive open 
arms serves as an index for emotional reactivity. 
 
Inverse agonist 
An inverse agonist (e.g. the CB1 receptor antagonist/inverse 
agonist Rimonabant) is an agent that binds to the same 
receptor binding-site as an agonist, but exerts the opposite 
pharmacological effects. 
 
Light/dark emergence test 
(EMT) 
Paradigm for measuring anxiety-related behaviors in rodents. 
The apparatus consists of a dark, enclosed and a highly 
illuminated open compartment. Exploration of the aversive 
open compartment serves as an index for emotional reactivity. 
 
Prepulse inhibition (PPI) of the 
ASR 
PPI is the natural reduction of the ASR if an acoustic, non-
startling prestimulus is presented shortly (30 - 500 msec) 
before the startling stimulus. PPI is used as an operational 
measure for sensorimotor gating mechanisms. 
 
Progressive ratio (PR) 
PR tasks serve as a measure in rodents for the motivational 
value of a reinforcer. Testing usually occurs in a Skinner box 
where animals perform a specific operant action (e.g. lever 
pressing) in order to recieve reinforcement. During testing, the 
operant requirements for reinforcement are steadily increased 
and animals are monitored for performance consistency. 
 
Tetrad of cannabinoid effects 
A series of physiological and behavioral tests used to measure 
the pharmacological effects of cannabinoids; including 
hypokinesia, hypothermia, catalepsy and antinociception.  
 
Wisconsin card sorting test 
(WCST) 
The WCST is a neuropsychological test that assesses the 
ability to display flexibility in the face of changing schedules of 
reinforcement. The participants respond to a series of stimuli 
where the rules about how to perform the task change from 






The identification of Δ9-tetrahydrocannabinol as the major psychoactive constituent of 
Cannabis sativa was a milestone in cannabinoid research that led to the discovery of the 
cannabinoid receptors CB1 and CB2 and the endocannabinoid signaling system. This 
evolutionarily ancient and widely distributed modulatory system participates in a multitude of 
neurophysiological processes such as reward-related behaviors, pain perception, emotional 
homeostasis, memory storage or motor control. The development of potent synthetic 
cannabinoid receptor agonists as well as antagonists/inverse agonists have contributed to a 
better understanding of cannabinoid pharmacology and the neurobiological mechanisms 
involved in behavioral effects of cannabinoids. This chapter introduces the endocannabinoid 
system and its role as a mediator of mechanisms of synaptic plasticity in the nervous system. 
Cannabinoid behavioral neuropharmacology is then reviewed and discussed, highlighting the 
challenges associated with mechanistic interpretation of the effects of cannabinoids on 
behavior. 
1. Cannabinoids and cannabinoid receptors 
 In 1964 Δ9-tetrahydrocannabinol (Δ9-THC) was identified as the main psychoactive 
constituent of the drug cannabis, which enabled investigation of the behavioral actions of 
“cannabinoids” in animal models. For example, in dogs Δ9-THC causes static ataxia and in 
mice Δ9-THC causes hypokinesia, hypothermia, catalepsy and antinociception. This “tetrad” 
of effects of Δ9-THC on mice has been formalised as a behavioral assay for cannabinoid-type 
compounds. Accordingly, the effects of Δ9-THC in the tetrad assay are mimicked by a variety 
of synthetic Δ9-THC analogues (e.g. CP 55940, HU-210) and by other compounds with 
cannabinoid-type pharmacology (e.g. WIN 55,212-2). Furthermore, investigation of the 
structure-activity relationships of Δ9-THC and other cannabinoids in the tetrad assay revealed 
stereoselectivity indicative of a mechanism of action involving interaction with specific 
receptor binding sites – hence the concept of “cannabinoid receptors” emerged. 
 Definitive evidence for the existence of cannabinoid receptors in the brain was first 
obtained from membrane binding assays employing a radiolabelled cannabinoid - [3H]CP 
55940. Furthermore, the pharmacological properties of cannabinoid binding sites in brain 
membranes in vitro correlate with the structure-activity relationships of cannabinoids in vivo, 
indicating that the behavioral actions of cannabinoids are mediated by a distinct receptor.  
The molecular identity of this receptor was determined in 1990 with the cloning and 
sequencing of a G-protein coupled receptor, which when expressed in cells confers 
responsiveness to Δ9-THC and other cannabinoids. This brain cannabinoid receptor is now 
known as CB1 to distinguish it from a structurally related cannabinoid receptor (CB2), which is 
predominantly associated with immune cells. Important evidence that CB1 is largely 
responsible for mediating the behavioral effects of cannabinoids has come from the finding 
that the classic “tetrad” of cannabinoid actions observed in wild-type mice (see above) are 
not observed in mice where the CB1 gene has been deleted (“CB1-knockout mice”).  
 Consistent with the diverse behavioral effects of cannabinoids in mice, the CB1 
receptor is both widely and abundantly expressed in the mammalian central nervous system 
(CNS). For example, high levels of CB1 expression are particularly noteworthy in the dorsal 
striatum and in neurons that project from the striatum to the substantia nigra, which probably 
explains why cannabinoids affect locomotor activity in mice and other mammals. Likewise, 
CB1 receptor expression in the dorsal horn of the spinal cord and in peripherally projecting 
neurons of the dorsal root ganglia has been linked with the anti-nociceptive actions of 
cannabinoids.  Detailed analysis of CB1 expression in the CNS using immunocytochemical 
techniques has revealed that CB1 receptors are specifically targeted to the axons and axon 
terminals of neurons that express the CB1 gene. This pattern of expression at a sub-cellular 
level is consistent with the inhibitory effects of cannabinoids on neurotransmitter release in 
vitro. Thus, cannabinoid activation of pre-synaptic CB1 receptors causes G-protein mediated 
inhibition of voltage-gated calcium channels, resulting in a transient reduction in 
neurotransmitter release. Longer-term inhibitory effects of cannabinoids on neurotransmitter 
release appear be mediated via mechanisms resulting from CB1-mediated inhibition of 
cAMP-dependent protein kinase signaling. 
 Our now detailed understanding of the molecular and cellular mechanisms by which 
cannabinoids affect neural activity and behavior has provided an important basis for 
assessing the risks associated with recreational use of cannabis. It has also informed 
strategies to develop cannabinoid compounds with potential therapeutic properties; for 
example, use of CB1 receptor agonists as analgesics or use of CB1 receptor antagonists (e.g. 
SR141716A or “rimonabant”) as a treatment for obesity.  However, equally importantly, 
research on cannabinoid action in the nervous system has revealed the existence of an 
endogenous cannabinoid signaling system with fundamental roles in mechanisms of synaptic 
plasticity. Thus, research on cannabinoid neuropharmacology now takes up a centre-stage 
position in 21st century neuroscience. 
 
2. Endocannabinoids: discovery, biosynthesis and inactivation. 
 The discovery of the G-protein coupled receptors CB1 and CB2 indicated that 
endogenous ligands for these receptors must exist and two derivatives of arachidonic acid 
were identified as candidate “endocannabinoids” in the 1990s – N-arachidonoylethanolamide 
(“anandamide”, AEA) and 2-arachidonoylglycerol (2-AG). Both AEA and 2-AG are present in 
the CNS, but 2-AG is much more abundant than AEA. Furthermore, obtaining evidence that 
these molecules bind to and activate CB1 receptors in vivo during normal brain function has 
been facilitated by molecular characterisation of enzymes that catalyse the synthesis or 
degradation of these molecules. 
The mechanisms by which AEA is synthesized in the brain are currently not known, 
although several candidate pathways have been proposed. However, an enzyme that 
catalyses degradation of AEA has been identified – fatty acid amide hydrolase (FAAH). 
Importantly, the brain content of AEA in FAAH-knockout mice is 15 fold higher than in wild-
type mice, providing compelling evidence that FAAH has a pivotal role in regulating AEA 
levels in the CNS. Furthermore, the enhanced basal level of AEA in the CNS of FAAH-
knockout mice causes hypoalgesia, which is at least in part mediated by CB1 receptors. The 
elevated levels of AEA in the CNS of FAAH-knockout mice does not appear to alter 
expression of CB1 receptors, but interpreting the physiological significance of phenotypes 
observed in FAAH-knockout mice is nevertheless complicated. Therefore, use of FAAH 
inhibitors to transiently inhibit FAAH activity is an attractive complementary approach for 
analysis of the role FAAH in regulation of endocannabinoid signaling. A wide-range of 
compounds that inhibit FAAH have been developed but potential off-target effects of some of 
these compounds (e.g. URB597) has complicated interpretation of their actions in vivo. 
However, some highly selective FAAH inhibitors have been developed (e.g. PF-3845), which 
has enabled investigation of the physiological and behavioral consequences of 
pharmacological inhibition of FAAH activity in vivo.  Interestingly, administration of PF-3845 
to mice does not mimic the tetrad of effects observed with Δ9-THC (see above) but it does 
cause elevation of AEA levels and CB1-mediated inhibition of neuropathic pain. Accordingly, 
FAAH inhibitors are considered to be potentially therapeutically useful because they may 
lack the psychoactive properties of Δ9-THC and other cannabinoids that bind directly to CB1 
receptors.   
The endocannabinoid 2-AG is synthesized in the brain by the enzyme diacylglycerol 
lipase alpha (DAGLα), which catalyses formation of 2-AG from arachidonic acid containing 
diacylglycerol. Evidence that DAGLα is the principal enzyme involved in biosynthesis of 2-AG 
in the brain has come from analysis of DAGLα-knockout mice, which have ~5-fold lower 
levels of 2-AG than wild-type mice. Furthermore, proof that 2-AG synthesized by DAGLα 
binds to CB1 receptors in vivo has been provided by the finding that CB1-mediated 
mechanisms of synaptic plasticity in several regions of the brain (see below) are absent in 
DAGLα-knockout mice. 
The principal enzyme in the brain responsible for inactivation of 2-AG is 
monoacylglycerol lipase (MAGL) and the key evidence for this has come from analysis of 
MAGL-knockout mice, which have ~10-fold higher CNS levels of 2-AG than wild-type mice. 
Furthermore, the elevation of 2-AG levels in the CNS of MAGL-knockout mice causes cross-
tolerance to the antinociceptive and hypothermic effects CB1 receptor agonists, providing 
further evidence that 2-AG synthesized in vivo binds to CB1 receptors. Importantly, the 
effects of MAGL gene knockout are to a large extent phenocopied by administration of 
selective MAGL inhibitors such as JZL184, which causes an 8-10 fold elevation in brain 2-AG 
levels when administered to mice, without affecting brain AEA levels. JZL184 causes 
hypomobility, hypothermia and analgesia in mice, partially mimicking the tetrad effects of Δ9-
THC, although the hypothermic and analgesic effects of JZL184 are lower in magnitude than 
for direct CB1 agonists and JZL184 does not induce catalepsy. Thus, 2-AG appears to have 
a widespread role in the brain as an endogenous agonist for CB1 receptors and accordingly 
the behavioral effects of Δ9-THC in mice could be considered equivalent, at least in part, to 






3. Endocannabinoid signaling as a mechanism of synaptic plasticity 
 Characterisation of the molecular components that mediate and regulate 
endocannabinoid signaling in the CNS has not only enabled interpretation of the behavioral 
effects of cannabinoids, it has also provided the basis for discovery of mechanisms of 
synaptic plasticity at a cellular and sub-cellular level. Thus in 1998, based upon what was 
known at the time about the molecular neuroanatomy of the endocannabinoid (ECB) system, 
it was first proposed that endocannabinoids may mediate a particular form of synaptic 
plasticity in which endocannabinoids are synthesized post-synaptically but act on pre-
synaptic CB1 receptors to inhibit neurotransmitter release – i.e. retrograde synaptic signaling. 
In 2001/2002 an elegant series of experimental studies demonstrated that this hypothesis 
was indeed correct. Thus, transient depolarisation of principal neurons in several regions of 
the brain causes CB1-mediated inhibition of pre-synaptic release of the inhibitory 
neurotransmitter GABA (depolarisation-induced suppression of inhibition or DSI) and/or CB1-
mediated inhibition of pre-synaptic release of the excitatory neurotransmitter glutamate 
(depolarisation-induced suppression of excitation or DSE). Furthermore, DSI and DSI are 
completely abolished in DAGLα-knockout mice, indicating that it is 2-AG that mediates these 
particular forms of synaptic plasticity. Consistent with the notion that 2-AG is synthesized 
post-synaptically but acts pre-synaptically, its biosynthetic enzyme DAGLα is concentrated 
post-synaptically in dendritic spines apposed to CB1-expressing axon terminals. Conversely, 
the degradative enzyme MAGL is localised pre-synaptically in axons and the duration of DSI 
and DSE in MAGL-knockout mice is prolonged when compared to wild-type mice, indicating 
that MAGL controls the time course of 2-AG/CB1-mediated retrograde synaptic signaling. 
Accordingly, the MAGL inhibitor JZL184 also prolongs the duration of DSI and DSE in wild-
type mice. In contrast, FAAH inhibitors do not affect the duration of DSI and DSE, indicating 
that it is only 2-AG and not AEA that mediates these particular forms of endocannabinoid-
mediated synaptic plasticity. Clearly, transient post-synaptic depolarisation of neurons that is 
induced experimentally using electrodes in DSI/DSE protocols may only partially recapitulate 
synaptic phenomena that occur physiologically. Nevertheless, it is thought that DSI and DSE 
are manifestations of Ca2+ stimulation of basal DAGLα-dependent 2-AG synthesis, whilst 
basal DAGLα-dependent 2-AG synthesis is thought to be driven by metabotropic receptors 
that couple via Gq/11-type proteins to stimulate phospholipaseCβ-mediated formation of DAG. 
  In addition to short-term mechanisms of synaptic plasticity such as DSI and DSE, 
there is evidence that endocannabinoid signaling also mediates long-term depression (LTD) 
of synaptic transmission. This was first observed in the striatum, where stimulation of cortical 
glutamatergic input causes activation of postsynaptic metabotropic glutamate receptors, 
leading to endocannabinoid/CB1–mediated long-term depression of transmission at 
excitatory cortico-striatal synapses. Endocannabinoid/CB1–mediated LTD has subsequently 
been reported in other regions of the brain. Furthermore, there is evidence that again it is 
postsynaptic formation of 2-AG that mediates this particular form of long-term synaptic 
plasticity. However, the role of DAGLα as the source of 2-AG in endocannabioid/CB1–
mediated LTD has as yet, to the best of our knowledge, not been definitively proven using 
DAGLα-knockout mice and/or DAGLα inhibitors. 
 The physiological roles of AEA as an endogenous agonist for CB1 receptors in the 
CNS are currently less well characterised when compared to 2-AG. This in part reflects 
incomplete knowledge of the mechanisms by which AEA is synthesized in the brain. 
However, we do have detailed information on anatomical distribution of the AEA-degrading 
enzyme FAAH. FAAH is widely expressed in the brain and is located in the somatodendritic 
compartment of principal neurons in many regions of the brain, including the olfactory bulb, 
neocortex, hippocampus, amygdala, thalamus and cerebellum. FAAH is also expressed in 
oligodendrocytes and ventricular ependymal cells, but it seems unlikely that expression of 
FAAH in these cell types directly impacts on mechanisms of synaptic plasticity. The 
functional significance of postsynaptic neuronal expression of FAAH in relation to retrograde 
synaptic signaling mediated by endocannabinoids is not known. One possibility is that FAAH-
mediated regulation of postsynaptic AEA biosynthesis influences the temporal and spatial 
dynamics of retrograde endocannabinoid signaling, but arguing against such a role is the 
finding that FAAH inhibitors, unlike MAGL inhibitors, do not enhance the duration of 
endocannabinoid-mediated mechanisms of synaptic plasticity such as DSI and DSE. 
However, it has been found that overexpression of FAAH in cultured neurons shortens the 
duration of DSE. Furthermore, there is also evidence that AEA may mediate mechanisms of 
synaptic plasticity via CB1-independent molecular pathways. Thus, postsynaptic elevation of 
intracellular AEA levels is thought to cause LTD via a mechanism mediated by the cation 
channel TRPV1, which results in internalisation of post-synaptic AMPA-type glutamate 
receptors. Clearly, our understanding of the physiological roles of AEA in the brain is far from 
complete and further research is needed.  
 Having reviewed the molecular and cellular basis of cannabinoid action in the nervous 
system and the physiological mechanisms of endocannabinoid signaling, we have a basic 
framework for understanding the effects that cannabinoids have on whole-animal behavior. 
However, given the widespread distribution of CB1 receptor expression in the CNS and the 
complex biochemistry of endogenous cannabinoid signaling, acquiring a mechanistic 
understanding of the behavioral actions of cannabinoids is challenging. Nevertheless, in the 
following section of this article we will review a variety of behavioral effects of cannabinoids 
that have been reported and discuss these with reference to the molecular and cellular level 
processes outlined above. 
 
4. Behavioral effects of cannabinoids  
  The neuropharmacological effects of cannabinoids are as diverse as the expression 
of cannabinoid receptors in the CNS. The regional distribution of CB1 receptors throughout 
the mammalian CNS corresponds well with the behavioral effects of cannabinoids observed 
in animal experiments and in human cannabis users. The role of the CB2 receptor in the 
brain has recently received increasing attention and its possible function in CNS processes is 
heavily debated. However, although most cannabinoid receptor agonists exhibit non-seletive 
affinity for CB1/CB2 receptors, the specific central pharmacological effects of CB2 receptor 
agonists/antagonists are not well studied yet. We are therefore going to focus on the 
neuropharmacology of the CB1 receptor for the present chapter. Various studies indicate that 
aside from dosage or route of administration, cannabinoid effects might vary greatly with the 
developmental stage and age (e.g. childhood, puberty). The following section will therefore 
exclusively review the most prominent neurobehavioral effects of cannabinoids in adult 
organisms. 
 
4.1 Locomotor activity 
The initiation of locomotor activity depends upon processing of internal motivational 
and external sensoric stimuli and is mediated by interactions between limbic and motor 
systems. Cannabinoids profoundly affect locomotion, which is consistent with the abundant 
expression of the CB1 receptor in neurons of the cerebellum and the basal ganglia. In 
particular, the basal ganglia represent an important structure for the regulation and initiation 
of motor activity, since they integrate cortical information into the coordination and 
organization of motor sequences and complex behaviors. Glutamate, GABA, and dopamine 
are among the most important neurotransmitters that participate in the control of basal 
ganglia function, and all three transmitter systems are modulated by cannabinoids. By 
regulating glutamatergic and GABAergic systems within the same neuronal network, 
cannabinoid receptors can modulate both inhibitory and excitatory neuronal transmission in 
the basal ganglia and may thus provide dual regulation of movement. CB1 receptors are 
abundantly expressed on striatal GABAergic medium-spiny projection neurons but are also 
expressed on the terminals of glutamatergic cortical inputs to the striatum. In the cerebellar 
cortex, CB1 receptors are abundantly expressed on glutamatergic and GABAergic inputs to 
Purkinje cells.  
 In humans, cannabis ingestion clearly affects motor performance, in particular 
balance and psychomotor control, and higher doses have been shown to induce 
hypokinesia, catalepsy, and ataxia. From experimental research in rodents (and dogs) it is 
known that synthetic and natural cannabinoid agonists (e.g. Δ9-THC, WIN 55,212-2, CP 
55940) exert dose-dependent biphasic (or even triphasic) effects on locomotor activity in an 
open field (see table 1). While very low doses appear to decrease activity in rodents, 
moderate to low doses have been found to stimulate activity and high doses induce 
catalepsy and inhibit locomotor activity. Additionally, administration of phytocannabinoid 
agonists (e.g. Δ9-THC) was found to induce circling behavior and hyperreflexia. These effects 
appear to be mediated directly by the CB1 receptor since the CB1 receptor antagonist/inverse 
agonist SR141716A counteracts most of the alterations in locomotor activity induced by 
application of CB1 receptor agonists. 
 Conflicting results have also been reported for the pharmacological effects of CB1 
receptor antagonists (e.g. SR14716A, AM251) on locomotor activity. SR141716A was found 
not to affect activity levels on its own in rats and dogs, whereas one study in mice reported 
the induction of hyperactivity. Additionally, further studies in rats even demonstrated 
decreased activity in rats after application of high doses of AM251. These diverging 
behavioral effects might partially emerge from the inverse agonistic properties of these 
substances, which might induce similar biphasic dose-dependent effects as have been 
observed for CB1 receptor agonists.  
 Aside from its effects on the activity level, SR141716A was also found to increase 
self-grooming behavior and scratching, and to reduce exploratory behavior. These findings 
raise an important issue for the behavioral testing of cannabinoid effects. Most studies 
investigating locomotor activity assess the performance of the animals in an open field. 
However, since cannabinoids are well known to modulate emotional behavior, the decrease 
in locomotion might not always be related to an inhibition of locomotor control, but might also 
vary with increased or decreased anxiety and the exploratory drive of the animals. 
 In line with the behavioral effects of synthetic and phytocannabinoid agonists, 
application of the endocannabinoid AEA was also found to induce biphasic effects on 
locomotor activity. Surprisingly, administration of pharmacological compounds that inhibit 
FAAH (e.g. URB597, PF-3845), and thereby increase the availability of AEA, do not affect 
locomotor behavior in rodents. In contrast, systemic injections of MAGL inhibitors (e.g. 
JZL184) or combined FAAH/MAGL inhibitors (e.g. JZL195) were found to attenuate 
locomotor activity and induce hyperreactivity, suggesting a main modulatory role for 2-AG in 
the regulation of locomotor behavior. Finally, catalepsy was only observed after combined 
pharmacological inhibition of FAAH and MAGL. 
 Taken together, a multitude of studies demonstrate that cannabinoids exert distinct 
modulatory effects on locomotor activity that vary with dosage and test conditions, but the 
detailed underlying mechanisms for cannabinoid-mediated effects on motor control remain 
yet to be identified.
4.2 Reward-related behavior  
  From an evolutionary perspective it is highly important to reinforce processes that are 
crucial for survival and reproduction (e.g. feeding and sexual behavior). Events, behavioral 
actions or objects that satisfy these basic needs are therefore generally considered as 
natural (non-drug) rewards. These processes are so elementary for survival of an individual 
that it is not surprising at all for a phylogenetically ancient signaling system, such as the ECB 
system, to be strongly involved in reward processing. Several brain structures, neurocircuits 
and related transmitter systems, known as the “reward system”, can be assigned to the main 
sub-components of reward: learning, hedonic/pleasurable experiences, and motivation. This 
brain reward system is not only crucial for the processing of natural rewards, but at the same 
time provides the basis for drug abuse and drug addiction. Along with the dopaminergic, the 
glutamatergic, and the endogenous opioid system, the ECB system has emerged recently as 
a key neurochemical mediator of reward processes. Although cannabinoids have been 
shown to affect and interact with all naturally rewarding processes (feeding, sexual behavior, 
social behavior, maternal behavior etc.) as well as with a variety of drugs of abuse (ethanol, 
nicotine, psychostimulants, opioids etc.), a complete description of all these pharmacological 
processes would be beyond the scope of the present chapter. We therefore focus here 
exemplarily on the modulatory role of cannabinoids on the rewarding effects palatable food. 
  CB1 receptors are widely distributed throughout the brain reward circuits and exert an 
important modulatory influence on all other neurotransmitter systems involved in the 
mediation of reward-related behaviors. A close interaction between the ECB system and the 
glutamatergic system is well established in the brain reward system, since CB1 receptors are 
densely located on glutamatergic synapses. Likewise, CB1 and µ-opioid receptors share a 
similar distribution throughout the reward circuits and a co-localization of both receptors has 
been shown for example in the nucleus accumbens and the dorsal striatum. Additionally, 
heterodimerization of CB1 receptors with µ-, κ-, and δ-opioid receptors has been reported. 
Although the question as to whether CB1 receptors are located directly on dopaminergic 
neurons is still up for debate, an indirect cannabinoid-mediated stimulation of dopaminergic 
signaling, mainly by disinhibition of GABAergic negative control over dopaminergic neurons 
in the ventral tegmental area (VTA) has been described in various studies. Furthermore, 
endocannabinoids are also necessary for the induction of several dopamine-dependent or 
independent long-term forms of synaptic plasticity in the VTA and in the terminal regions of 
dopaminergic neurons. 
  It has been well known for centuries that cannabinoids can induce euphoric and 
rewarding effects in humans and animals. One of the most prominent features of cannabis 
consumption is an initial period of euphoria and relaxation. These pleasurable subjective  
effects also contribute to its abuse. Aside from the euphoric effects, ingestion of cannabis 
preparations is well known to induce a ravenous appetite, particularly for sweet and palatable 
food, termed “the munchies”. Many of these more anecdotal reports on the rewarding 
properties of cannabis and cannabinoids have been comfirmed by recent scientific studies in 
humans and animals and therefore growing evidence indicates that the ECB system is a 
strong modulator of various aspects of reward processing. The following section will focus on 
pharmacological effects of cannabinoids on motivational, consummatory and hedonic 
aspects of reward-related behaviors for palatable food rewards (see table 2).  
 Stimulatory effects on (palatable) food ingestion have been described for different 
cannabionid agonists and endocannabinoids in various studies. For example, Δ9-THC, AEA 
and 2-AG increase the preference for and intake of food or sucrose and the synthetic 
cannabinoid agonist CP 55940 increases the consumption of palatable solutions in rats. 
Furthermore, the motivation to actively respond for a palatable food reward, as measured by 
progressive-ratio (PR) schedules in a Skinner box, appears to be increased by administration 
of lower doses of cannabinoid agonists, but was also found to be decreased at higher doses. 
Additionally, cannabinoid effects on the hedonic value of food were addressed by taste 
reactivity studies which provide important information on the liking of palatable food rewards. 
Here it was shown that administration of AEA and Δ9-THC increases consumption and oral 
“liking” responses for palatable liquids.  
 CB1 receptor antagonists, such as SR141716A or AM251, have been shown to inhibit 
palatable food intake. However, the precise mechanism through which CB1 antagonism 
inhibits feeding has not been completely clarified thus far. Specifically, it is not known 
whether reduced feeding is induced by decreased appetite and attenuated hedonic value of 
food, or if side effects, such as motor slowing, incoordination, nausea, or substitute behaviors 
play a role. While SR141716A does not produce overt signs of sedation or motor slowing, 
other effects, such as induction of grooming, scratching, and head twitching, as well as 
reductions in spontaneous locomotion have been found at higher doses. However, an 
inhibition of CB1 receptors has been found to decrease oral liking responses in taste 
reactivity studies. 
 The pharmacological effects of FAAH and MAGL inhibition on food reward are not 
well studied yet but simultaneous administration of the FAAH inhibitors URB597 or AM374 
together with AEA seems to potentiate AEA effects. 
4.3 Cognition 
  Cognition refers to all mental processes involved in processing and gaining of 
information, knowledge and comprehension. These processes include attention, thinking, 
remembering, problem solving, planning, behavioral flexibility and decision-making. Higher- 
order cognitive (or executive) functions are mediated mainly by fronto-striatal brain areas in 
both humans as well as rodents and high densities of CB1 receptors have been described in 
frontal cortical and striatal regions. More specifically, CB1 receptors have been identified on 
GABAergic, glutamatergic, noradrenergic as well as serotonergic neurons throughout frontal 
cortical regions and have been reported to enhance dopamine transmission in the medial 
prefrontal cortex and the nucleus accumbens in an indirect manner. In particular the ability of 
cannabinoids to modulate dopaminergic neurotransmission appears to be highly important, 
since dopamine signaling is crucially involved in executive functioning. A very high density of 
CB1 receptors is also present in the hippocampus, where cannabinoids might exert their 
adverse effects on (spatial) memory performance. They are abundantly expressed on the 
terminals of hippocampal GABAergic basket cell interneurons in the CA1-CA4 field, as well 
as on GABAergic neurons in the dentate gyrus and to a lesser extent in glutamatergic 
hippocampal pyramidal cells and mossy cells.  
  It is well established that the ECB system plays a major role in cognitive processing. 
The following section will provide an overview of the pharmacological effects of cannabinoids 
on executive functions, including short-term mnemonic and attentional processing, as well as 
behavioral flexibility (see table 3). 
  Disruptions of attentional and mnemonic processing are the most consistent 
observations of cannabis intoxication in humans. These findings are consistent with a 
number of studies in laboratory rodents demonstrating that various cannabinoid agonists 
impair attention and memory functioning. Memory deficits have been reported after 
administration of phytocannabinoids (e.g. Δ9-THC), synthetic cannabinoids (e.g. WIN 55,212-
2) and endocannabinoids for working memory tasks, spatial learning as well as recognition 
memory abilities. It appears that cannabinoids interfere mainly with memory acquisition, early 
consolidation and facilitate memory extinction, rather than affecting memory retrieval. This 
would be consistent with the observation that pharmacological inactivation of CB1 receptors 
facilitates induction and maintenance of hippocampal long-term potentiation. With respect to 
the modulation of attention, the pharmacological effects of cannabinoids are not as 
conclusive as for memory processing, which might be related to the fact that most tasks 
applied are susceptible to disturbances in locomotor control. Dose-dependent inhibitory 
effects (or in some cases no effects) on attentional processing have been reported in 
different paradigms, such as prepulse inhibition (PPI) of the acoustic startle reflex (ASR) or 
reaction time tasks (RTT).  
  Behavioral flexibility, the ability to adapt to changing environments, is an important 
cognitive skill, and requires the capacity to adjust behavioral strategies and to suppress 
acquired response patterns. An important role of the ECB system in these processes has 
been suggested by various studies in humans and rodents. In humans, heavy cannabis use 
was shown to be associated with deficits in behavioral flexibility (or reversal learning) 
measured in a Wisconsin card sorting test (WCST). Likewise, administration of different 
cannabinoid agonists in laboratory rodents has also been found to impair cognitive flexibility 
in attentional set shifting tasks (ASST), developed as an equivalent to the human WCST, and 
in an olfactory go/no-go discrimination task and a cross maze paradigm. 
  CB1 receptor antagonists have been found to enhance attentional processing, short-
term memory functioning and behavioral flexibility, but also no effects on these cognitive 
processes were reported. In particular, memory acquisition appears to be improved by 
SR141716A or AM251, but controversial findings were reported on memory consolidation. 
  Surprisingly, FAAH inhibitors have been found to enhance learning in several 
procedures, although AEA inhibits memory functioning. The FAAH inhibitor OL-135 
enhanced the acquisition rate in a water maze test (although this effect was not found in an 
earlier study). Additionally, administration of URB597 was shown to enhance the acquisition 
of passive-avoidance learning, without affecting consolidation or retrieval. Interestingly, the 
enhancing effects of FAAH inhibition on passive-avoidance learning could be blocked not 
only by SR141716A but also by an antagonist of the PPAR-receptor, suggesting that FAAH 
inhibition might enhance memory by increasing the levels of the endogenous PPAR-α 
ligands N-oleoylethanolamine (OEA) and palmitoylethanolamide (PEA). In contrast, memory-
disrupting effects of URB597 have been reported in a delayed-non-match-to-sample task. 
The pharmacological effects of MAGL inhibitors or 2-AG on cognitive processing are not well 
studied yet and in particular the effects of both endocannabinoids on attentional processing 
and behavioral flexibility have to be further examined. Therefore, more studies are needed 





4.4 Emotional behavior 
  As described above, the main features of recreational cannabis use in humans are 
the euphoric and relaxing effects of the drug. However, aside from these pleasurable 
experiences, cannabis can also induce dysphoric reactions, including severe anxiety, panic 
and paranoia. Fear and anxiety are crucial and adaptive components of the overall stress 
response to threatening situations that might perturb homeostasis. Transient anxiety 
therefore elicits an appropriate response (e.g. escape or avoidance) and is of fundamental 
importance as a survival strategy for mammals. Anxious states are, thus, controlled by a 
highly complex system of both inhibitory and facilitatory mechanisms. Numerous 
interconnected limbic and cortical structures have been implicated in the modulation of 
anxious states that all express CB1 receptors (e.g. frontal cortex, amygdala, thalamus, 
nucleus accumbens, hippocampus etc.). 
  In animal experiments the term 'emotionality’ is classically used to conceptualize 
behavioral changes in an arousing context such as novel or anxiogenic environments or 
situations. Behavioral paradigms for emotional behavior in rodents therefore mainly assess 
innate (unconditioned) avoidance or conflict behaviors as well as conditioned aversion. The 
involvement of ECB signaling in the mediation of anxiety-related behaviors is very complex 
and only partially understood. Similar as in cannabis users, administration of cannabinoid 
agonists in rodents has been reported to induce anxiogenic as well as anxiolytic-like 
responses (see table 4). We are going to review pharmacological effects of cannabinoids on 
unconditioned anxiety-related behaviors in classical paradigms such as the elevated plus 
maze or the light/dark emergence test.  
  Synthetic and phytocannabinoid agonists have been reported in various studies to 
induce either anxiolytic- or anxiogenic-like reactions, depending upon dosage, test paradigm, 
the test context and conditions (e.g. light intensity; familiar vs, unfamiliar environment), 
species or genetic strain. Generally, low doses tend to reduce and high doses tend to 
increase, anxiety-like behaviors. However, in particular in mice, the genetic background of 
the animals seems to interfere with pharmacological effects on anxiety-related behaviors. 
 Similar conflicting effects have been reported for CB1 receptor antagonists, which 
have been found to induce anxiogenic as well as anxiolytic behavioral responses. Thus, in 
paradigms based on innate fear reactions, cannabinoid pharmacology may either enhance or 
attenuate anxiety-like behavior. 
 Central administration of methanandamide (a metabolically stable analogue of AEA) 
directly into the PFC revealed anxiolytic-like responses in rats in the EPM test for low doses, 
whereas high doses induced anxiogenic effects. Central administration of AEA in the 
amygdala revealed no effects on emotional behavior. Inhibition of FAAH or MAGL 
has been shown to reduce anxiety-like behaviors in different paradigms without affecting 






 Pain perception, an unpleasant sensory and/or emotional experience associated with 
actual or potential tissue damage, is an important component of the body's defense system 
that is essential for survival. Acute pain does not outlast the initiating painful stimulus (e.g. 
superficial wounds, chemicals or burns, ischemia and inflammation), whereas chronic pain 
outlasts the initiating (often unknown) stimulus. Cannabinoids have been used 
therapeutically for pain relief for many thousands of years, clearly indicating an involvement 
of the ECB system and cannabinoid pharmacology in nociception. 
  Endocannabinoids and CB1 receptors are present in the major pain pathways and 
strongly modulate pain processing through central (both spinal and supraspinal) and 
peripheral mechanisms, most probably through a close interaction with the endogenous 
opioid system but also opioid-independent mechanisms. Although CB2 receptors appear to 
be also important for pain processing, a description of these mechanisms would be beyond 
the scope of the present chapter, and we are therefore going to focus on CB1 receptor 
mediated pharmacological effects of cannabinoids on nociception.  
  CB1 receptor agonists exert antinociceptive and antihyperalgesic effects in various 
animal models of neuropathic and inflammatory pain, and are also effective against acute 
noxious stimuli (e.g. the tail-flick and hot-plate test). The antinociceptive effects produced by 
systemic administration of cannabinoids are attenuated following spinal transection, 
indicating an important role for supraspinal brain sites. In particular, the periaqueductal gray, 
the thalamus, the rostral ventromedial medulla and the amygdala appear to be important 
brain regions for cannabinoid analgesic action. Activation of these sites by endocannabinoids 
may, therefore, produce antinociception under physiological conditions. 
  The pharmacological effects of CB1 receptor antagonists are quite controversial. Initial 
studies with CB1 receptor antagonists, such as SR141716A, found no alterations on acute 
pain sensitivity (e.g. tail flick test or hot plate). In contrast, other studies reported 
hyperalgesic effects in the same test paradigms. In the formalin test of persistent pain, 
similar conflicting results have been described, as initial studies described a 
hyperalgesic activity for CB1 receptor antagonism which could not be confirmed in further 
studies. Therefore, the nociceptive properties of CB1 receptor antagonists/inverse agonists 
still need to to be clarified, although the existing data indicate that differences in the level of 
endogenous analgesic tone (dependent on stress effects, or other environmental factors of 
the pain models used) may contribute to the differences observed on pain processing. 
  Various studies indicate that administration of AEA or FAAH inhibitors (e.g. URB597, 
URB532, OMDM122) promotes analgesia, although the question of whether AEA exerts its 
antinociceptive effects via CB1 receptor-dependent or independent mechanisms is not 
completely clarified. Inhibition of FAAH induces CB1 receptor-dependent antinociceptive 
activity in several rodent pain models, including the formalin test, the carrageenan paw 
inflammation test, neuropathic pain and the hot-plate test. Similar anti-nociceptive effects 




 The complexity of the neuropharmacological effects of cannabinoids, some of which 
were reviewed exemplarily in the present chapter, reflects the importance and extensive 
modulatory role of the CB1 receptor and the ECB system in a multitude of CNS functions. 
However, this plethora of cannabinoid-mediated behavioral effects also emphasizes one of 
the major problems of neuropharmacological studies as well as limitations of the 
therapeutical use of cannabinoids, since it is not yet possible to clearly separate or 
independently investigate pharmacological effects of cannabinoids on specific behaviors. 
This is especially the case for pharmacological studies in rodents. Alterations in locomotor 
activity will always interfer with other behavioral tasks such as motivation, consummption, 
pain response, emotional reactions or cognitive behavior. Likewise, the emotional state of an 
animal might simply affect exploratory behavior and therefore reduce performance in 
motivational tasks or tests for cognitive function. Additionally, the modulatory influence of 
cannabinoids on food reward or pain processing might be problematic for the testing of 
cognitive behavioral tasks using either food or aversive events (e.g. foot shocks) as 
reinforcers. It is therefore absolutely crucial to be mindful of such possible confounding 
behavioral influences when performing neuropharmacological experiments with 
cannabinoids. 
  A further important issue in cannabinoid pharmacology are apparent conflicting 
findings (e.g. dose-dependent bi- or even triphasic effects, context-specificity), which have 
been best described for emotional behavior and locomotor control. A possible explanation for 
the complexity of cannabinoid effects might be provided by the ‘on-demand’ functions of the 
ECB system (depending on environmental stimuli and on the emotional state of an 
individual), and also by its fine-tuning of inhibitory and excitatory neuronal activity. Thus, the 
biphasic effects observed after CB1 receptor-activation are not necessarily contradictory, 
since the ECB system functions as a neuromodulator of excitatory and inhibitory 
neurotransmission by modulating the activity of both GABA- and glutamate-release, which 
represent the two major opposing systems that control many neurophysiological processes. 
It therefore appears that ECB signaling has an important role in maintaining homeostasis by 
dampening excessive neuronal responses induced by environmental challenges, and is 
therefore activated by relatively high levels of synaptic activity. As a result, cannabinoids 
selectively affect heterogeneous neurons that may have differential effects on the behavioral 
response. Interfering with such a complex regulatory process might therefore lead to 
complex and situation-dependent effects. 
  Taken together, more research on the complex pharmacology of cannabinoids is still 
needed to further clarify the detailed neurphysiological effects and most importantly to shed 
light on the underlying neurobiological mechanisms. Gaining greater knowledge of the 
functionality and neuropharmacology of this important neuromodulatory system is also 
mandatory in order to fully benefit from the valuable therapeutical potential of cannabinoids 





Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008). Enzymatic pathways that regulate 
endocannabinoid signaling in the nervous system. Chem Rev, 108, 1687-1707. 
 
Chevaleyre, V., Takahashi, K. A., and Castillo, P. E. (2006). Endocannabinoid-mediated 
synaptic plasticity in the CNS. Annu Rev Neurosci, 29, 37-76. 
 
Cravatt, B. F. and Lichtman, A. H. (2004). The endogenous cannabinoid system and its role 
in nociceptive behavior. J Neurobiol, 61, 149-160. 
 
Egertova, M., Cravatt, B. F., and Elphick, M. R. (2003). Comparative analysis of fatty acid 
amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of 
a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling.  
Neuroscience, 119, 481-496. 
 
Egertova, M. and Elphick, M. R. (2000). Localisation of cannabinoid receptors in the rat brain 
using antibodies to the intracellular C-terminal tail of CB1. J Comp Neurol., 422, 159-171. 
 
Elphick, M. R. and Egertova, M. (2001). The neurobiology and evolution of cannabinoid 
signalling. Philos Trans R Soc Lond B Biol Sci,. 356, 381-408. 
 
Fattore, L., Melis, M., Fadda, P., Pistis, M., and Fratta, W. (2010). The endocannabinoid 
system and nondrug rewarding behaviours. Exp Neurol, 224, 23-36. 
 
Guindon, J. and Hohmann, A. G. (2009). The endocannabinoid system and pain. CNS and 
Neurol Disord Drug Targets, 8, 403. 
 
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., 
Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002). 
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. 
Pharmacol Rev, 54, 161-202. 
 
Moreira, F. A. and Lutz, B. (2008). The endocannabinoid system: emotion, learning and 
addiction. Addict Biol, 13, 196-212. 
 
Oudin, M. J., Hobbs, C., and Doherty, P. (2011). DAGL-dependent endocannabinoid 
signalling: roles in axonal pathfinding, synaptic plasticity and adult neurogenesis. Eur J 
Neurosci, 34, 1634-1646. 
 
Pattij, T., Wiskerke, J., and Schoffelmeer, A. N. (2008). Cannabinoid modulation of executive 
functions. Eur J Pharmacol, 585, 458-463. 
 
Rodriguez de Fonseca, F., Del Arco, I., Martin-Calderon, J. L., Gorriti, M. A., and Navarro, M. 
(1998). Role of the endogenous cannabinoid system in the regulation of motor activity. 
Neurobiol Dis, 5, 483-501. 
 
Schneider, M. (2008). Puberty as a highly vulnerable developmental period for the 
consequences of cannabis exposure. Addict Biol, 13, 253-263. 
 
Zanettini, C., Panlilio, L. V., Alicki, M., Goldberg, S. R., Haller, J., and Yasar, S. (2011). 
Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front 








Behavioral biology, preclinical animal 
studies of addiction  37 




Behavioral biology, preclinical animal 




Spanagel Neuropharmacology/Imaging/Genetics 278 
Neuroimaging in 
cannabis users   
 
